Abstract:Newborn screening (NBS) for severe combined immunodeficiency (SCID) has been introduced in various countries with the aim of reducing morbidity and mortality. However, studies analyzing outcomes before and after the implementation of NBS programs remain limited. This study sought to compare the outcomes of SCID patients identified through Switzerland's national SCID NBS program, introduced in January 2019, with those of a historical cohort diagnosed between 2007 and 2019. The study included seven patients (32%) identified through NBS, and 15 (68%) born before NBS implementation and diagnosed based on clinical signs. Children in the NBS group were younger at diagnosis (median age 9 days vs 9 months, P = .002) and at hematopoietic stem cell transplantation (HSCT, median age 5 months vs 11 months, P = .003) compared to the clinical group. The NBS group had a lower incidence of infections before HSCT (29% vs 93%, P = .004). Although not statistically significant, the overall survival rate on last follow-up was higher in the NBS group (86% vs 67%, P = .62). Importantly, patients with active infections undergoing HSCT had a significantly lower overall survival probability compared to those without ( P = .01). In conclusion, the introduction of NBS in Switzerland has led to earlier and often asymptomatic diagnosis of affected children, enabling timely intervention, infection prevention, and prompt treatment. These factors have contributed to higher survival rates in the NBS group. These findings underscore the critical importance of NBS for SCID, offering potential life-saving benefits through early detection and intervention.

What problem does this paper attempt to address?

This paper aims to explore the impact of the Newborn Screening (NBS) program in Switzerland on the mortality and morbidity of children with Severe Combined Immunodeficiency (SCID). Specifically, the study compared the outcome differences between patients diagnosed through the national SCID NBS program and those diagnosed due to clinical symptoms before the implementation of NBS. ### Research Background Severe Combined Immunodeficiency (SCID) is a rare but fatal hereditary disease. Due to the underdeveloped immune system, patients are extremely susceptible to infections. Early diagnosis and treatment are crucial for improving patients' survival rates and reducing complications. The introduction of the Newborn Screening (NBS) program aims to detect SCID early, so as to carry out timely intervention and treatment and reduce the mortality and morbidity of children. ### Research Objectives The main objective of this study is to evaluate the effectiveness and benefits of the NBS program by comparing the situations of SCID patients before and after the implementation of the NBS program. Specific objectives include: 1. Compare the differences between NBS group and clinical group patients in terms of diagnosis age, Hematopoietic Stem Cell Transplantation (HSCT) age, and infection incidence. 2. Analyze whether the implementation of the NBS program has improved the survival rate of patients. ### Research Methods - **Data Collection**: Retrospectively collect the electronic health records of all SCID or atypical SCID patients diagnosed at the Children's Hospital of the University of Zurich in Switzerland from 2007 to 2020. - **Grouping**: Classify patients born after the implementation of the NBS program in January 2019 as the NBS group, and those born before as the clinical group. - **Statistical Analysis**: Use Fisher's exact test and Mann - Whitney U test to compare categorical and continuous variables, and use Kaplan - Meier estimator, Cox regression and log - rank test for survival analysis. ### Main Findings - **Diagnosis Age**: The diagnosis age of patients in the NBS group was significantly lower than that in the clinical group (the median was 9 days and 9 months respectively, P = 0.002). - **HSCT Age**: The age at which patients in the NBS group received HSCT was also significantly lower (the median was 5 months and 11 months respectively, P = 0.003). - **Infection Incidence**: The infection incidence of patients in the NBS group before HSCT was significantly lower than that in the clinical group (29% vs 93%, P = 0.004). - **Survival Rate**: Although the overall survival rate in the NBS group was higher (86% vs 67%, P = 0.62), the difference did not reach statistical significance. - **The Impact of Infection on Survival Rate**: The survival rate of patients with active infections at the time of HSCT was significantly lower (P = 0.01). ### Conclusion The research results show that the NBS program implemented in Switzerland can diagnose children with SCID earlier, enabling them to receive treatment before being asymptomatic or infected, thereby significantly reducing the infection rate and improving the survival rate. These findings emphasize the importance of the NBS program in the early detection and intervention of SCID and are helpful for saving more children's lives.

Reducing Mortality and Morbidity in Children with Severe Combined Immunodeficiency in Switzerland: the Role of Newborn Screening

[Newborn screening for severe combined immunodeficiencies (SCID) in Germany]

[Advances in Newborn Screening and Immune System Reconstitution of Severe Combined Immunodeficiency].

Efficient screening strategies for severe combined immunodeficiencies in newborns

Newborn screening for severe combined immunodeficiency in Malaysia: current status, challenges and progress

A Unique Comprehensive Model to Screen Newborns for Severe Combined Immunodeficiency-An Ontario Single-Centre Experience Spanning 2013-2023

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Paving the way in implementation of SCID newborn screening in developing nations: feasibility study and strategies to move forward in Malaysia

Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency

Cystic fibrosis newborn screening in Switzerland – evaluation and scenarios for improvement after 11 years of follow-up

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results

A Modular Genetic Approach to Newborn Screening from Spinal Muscular Atrophy to Sickle Cell Disease—Results from Six Years of Genetic Newborn Screening

Positive impacts of universal newborn screening on the outcome of children with sickle cell disease in the province of Quebec: A retrospective cohort study

Why newborn screening for severe combined immunodeficiency is essential: a case report

Newborn Screening for Inherited Metabolic Diseases Using Tandem Mass Spectrometry in China: Outcome and Cost-Utility Analysis

The Alberta Newborn Screening Approach for Sickle Cell Disease: The Advantages of Molecular Testing

Severe combined immunodeficiency in Serbia and Montenegro between years 1986 and 2010: a single-center experience

Severe combined immunodeficiency with a homozygous c.464T>C (p.Leu155Pro) mutation in the RAG2 gene in a country without neonatal screening: Report of two clinical cases

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Screening for Primary Immunodeficiency Diseases by Next‐generation Sequencing in Early Life